Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 1
1994 8
1995 7
1996 4
1997 7
1998 4
1999 4
2000 11
2001 9
2002 9
2003 10
2004 15
2005 16
2006 15
2007 20
2008 26
2009 25
2010 37
2011 54
2012 54
2013 66
2014 55
2015 65
2016 54
2017 88
2018 115
2019 106
2020 125
2021 189
2022 201
2023 55
Text availability
Article attribute
Article type
Publication date

Search Results

1,310 results
Results by year
Filters applied: . Clear all
Page 1
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: pei l. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Clinical Trial.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Usmani SZ, et al. Among authors: pei l. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388396 Clinical Trial.
AP-1 activation mediates postnatal cardiomyocyte maturation.
Zhang H, Pei L, Ouyang Z, Wang H, Chen X, Jiang K, Huang S, Jiang R, Xiang Y, Wei K. Zhang H, et al. Among authors: pei l. Cardiovasc Res. 2022 May 31:cvac088. doi: 10.1093/cvr/cvac088. Online ahead of print. Cardiovasc Res. 2022. PMID: 35640820
Spotlight on USP4: Structure, Function, and Regulation.
Hu B, Zhang D, Zhao K, Wang Y, Pei L, Fu Q, Ma X. Hu B, et al. Among authors: pei l. Front Cell Dev Biol. 2021 Feb 18;9:595159. doi: 10.3389/fcell.2021.595159. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33681193 Free PMC article. Review.
1,310 results